MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
long-term debt, net
$65,346K
Proceeds from exercise of
options into ordinary...
$179K
Net cash provided by
financing activities
$65,204K
Canceled cashflow
$321K
Decrease in cash and cash
equivalents
-$800K
Canceled cashflow
$65,204K
Accounts payable and
accrued expenses
$7,629K
Share-based compensation
$4,627K
Amortization of discount on
long-term debt
$1,974K
Accrued financing on
prepaid forward...
$1,059K
Amortization of right of use
assets
$577K
Depreciation and
amortization
$75K
Amortization (accretion) on
marketable securities
-$26K
Maturities of marketable
securities
$4,146K
Principal payments on
finance leases
$321K
Net cash used in
operating activities
-$45,316K
Canceled cashflow
$15,967K
Net cash used in
investing activities
-$20,688K
Canceled cashflow
$4,146K
Net loss
-$23,574K
Accounts receivable, net
$22,330K
Prepaid expenses and
other current assets
$4,858K
Inventory
$4,457K
Employee related accrued
expenses
-$3,679K
Other non-current
assets
$2,332K
Lease liabilities
-$53K
Purchases of marketable
securities
$24,780K
Purchases of property and
equipment
$54K
Back
Back
Cash Flow
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN)
source: myfinsight.com